Alkermes (ALKS) CMO sells 9K shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 Ordinary Shares at an exercise price of $19.34 per share and acquired the related shares. On the same date, he sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share in an open-market transaction.
Both the option exercise and the share sale were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 85,389 Ordinary Shares. The options exercised were fully vested in accordance with their terms, and no remaining derivative positions are shown in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 9,000 shares ($319,604)
Net Sell
3 txns
Insider
Hopkinson Craig C.
Role
EVP R&D, Chief Medical Officer
Sold
9,000 shs ($320K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 5,000 | $0.00 | -- |
| Exercise | Ordinary Shares | 5,000 | $19.34 | $97K |
| Sale | Ordinary Shares | 9,000 | $35.5116 | $320K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 16,356 shares (Direct);
Ordinary Shares — 94,389 shares (Direct)
Footnotes (1)
- This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.50 to $35.62. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. These options are fully vested in accordance with their terms.
Key Figures
Options exercised: 5,000 shares
Exercise price: $19.34/share
Shares sold: 9,000 shares
+3 more
6 metrics
Options exercised
5,000 shares
Employee Stock Options exercised at $19.34 on April 1, 2026
Exercise price
$19.34/share
Conversion price for 5,000 Employee Stock Options
Shares sold
9,000 shares
Ordinary Shares sold in open market on April 1, 2026
Weighted average sale price
$35.5116/share
Sales executed between $35.50 and $35.62 per share
Shares held after transactions
85,389 shares
Direct Ordinary Share holdings after exercise and sale
Rule 10b5-1 plan adoption date
March 14, 2025
Governs the reported option exercise and share sale
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (Right to Buy), weighted average price, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (Right to Buy) financial
"security_title: Employee Stock Option (Right to Buy)"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested financial
"These options are fully vested in accordance with their terms."
FAQ
What did Alkermes (ALKS) executive Craig C. Hopkinson report in this Form 4?
Craig C. Hopkinson reported exercising stock options for 5,000 Ordinary Shares and selling 9,000 Ordinary Shares. Both transactions occurred on April 1, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025.
What options did Craig C. Hopkinson exercise in Alkermes (ALKS) stock?
He exercised Employee Stock Options covering 5,000 Ordinary Shares at an exercise price of $19.34 per share. The filing notes these options were fully vested in accordance with their terms and had an original expiration date of February 22, 2031.
Were Craig C. Hopkinson’s Alkermes (ALKS) trades made under a Rule 10b5-1 plan?
Yes. Both the option exercise and the subsequent sale were effected under a Rule 10b5-1 trading plan. The filing states this plan was adopted by the reporting person on March 14, 2025, indicating the transactions were pre-arranged rather than discretionary.
Does the Alkermes (ALKS) Form 4 show any remaining derivative holdings for Craig C. Hopkinson?
The filing’s derivative summary is empty, indicating no remaining derivative positions are reported. The exercised options were fully vested, and after their conversion into 5,000 Ordinary Shares, only direct Ordinary Share holdings are shown for Hopkinson.